Nutex Health (NASDAQ:NUTX) Trading Up 5.1% – Still a Buy?

Nutex Health Inc. (NASDAQ:NUTX)’s stock price traded up 5.1% during trading on Wednesday . The stock traded as high as $196.79 and last traded at $197.6470. Approximately 82,116 shares changed hands during trading, a decline of 52% from the average session volume of 171,077 shares. The stock had previously closed at $188.10.

Analyst Upgrades and Downgrades

NUTX has been the subject of a number of research analyst reports. Weiss Ratings raised Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, July 28th. Zacks Research upgraded Nutex Health from a “hold” rating to a “strong-buy” rating in a research report on Monday. B. Riley Financial assumed coverage on Nutex Health in a research note on Friday, June 26th. They issued a “buy” rating and a $290.00 price objective for the company. Wall Street Zen downgraded Nutex Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Finally, Lake Street Capital restated a “buy” rating and issued a $310.00 price objective (up from $235.00) on shares of Nutex Health in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $300.00.

Nutex Health Stock Performance

The stock has a 50-day moving average of $170.85 and a 200 day moving average of $133.25. The stock has a market cap of $1.33 billion, a PE ratio of 7.61 and a beta of 0.24. The company has a quick ratio of 4.96, a current ratio of 5.00 and a debt-to-equity ratio of 0.59.

Nutex Health (NASDAQ:NUTX) last issued its earnings results on Thursday, August 6th. The company reported $9.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.95 by $4.43. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%.The company had revenue of $210.75 million during the quarter, compared to analysts’ expectations of $215.03 million. Equities analysts predict that Nutex Health Inc. will post 30.11 EPS for the current fiscal year.

Institutional Investors Weigh In On Nutex Health

Several hedge funds and other institutional investors have recently bought and sold shares of NUTX. Hussman Strategic Advisors Inc. acquired a new position in Nutex Health in the 4th quarter valued at about $3,457,000. Quantinno Capital Management LP purchased a new stake in shares of Nutex Health during the 1st quarter valued at approximately $843,000. First Trust Advisors LP raised its position in shares of Nutex Health by 60.0% during the 1st quarter. First Trust Advisors LP now owns 18,335 shares of the company’s stock valued at $1,743,000 after buying an additional 6,874 shares during the period. Empowered Funds LLC acquired a new position in Nutex Health in the first quarter valued at approximately $3,084,000. Finally, Winmill & CO. Inc. purchased a new position in Nutex Health in the second quarter worth approximately $11,168,000. 5.32% of the stock is currently owned by institutional investors and hedge funds.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight?loss services and behavioral health support. By combining in?person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost?effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail?anchored centers, offering treatment for non?life?threatening injuries and illnesses, preventive screenings and basic primary care.